[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Apparent reinfections in Brazil", "description": "Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence \n\nDepartamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo,\nDepartment of Infectious Diseases and Parasitises and Institute of Tropical Medicine of the Faculty of Medicine of the University of S\u00e3o Paulo, S\u00e3o Paulo, \n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00183-5/fulltext\n\nEuropean and Asian countries\n\nSecond wave, consistent with many remaining susceptible\n\nManaus, Brazil\n\nBlood donors, 76% had been infected by October 2020\n\nAlso, estimated attack rates in Amazon Basin, 70% \n\nEstimated SARS-CoV-2 attack rate in Manaus, above theoretical herd immunity threshold of 67%\n\n(based on a reproduction number of 3)\n\nBut January 2021\n\nManaus hospital admissions, 3,431\n\n(552 in Dec 1\u201319, 2020)\n\nMay to November, relaxation of control measures, low admissions for 7 months\n\nThere are at least four non-mutually exclusive possible explanations for the resurgence of COVID-19 in Manaus. \n\nWhy a resurgence of cases?\n\nFirst factor, first wave overestimated\n\nAttack rate could have been overestimated during the first wave\n\nJune, seroprevalence, 52\u00b75%\n\nSecond factor, waning immunity\n\nWaning of IgG antibody titres observed in blood donors \n\nMost of the SARS-CoV-2 infections in Manaus occurred 7\u20138 months before resurgence in January, 2021\n\n(No observed behaviour change in Manaus, reduced population mobility)\n\nIf resurgence in Manaus is due to waning, similar resurgence everywhere\n\n\n\nThird factor, antigenic escape\n\nNew SARS-CoV-2 lineages\n\nCirculating in Brazil, B.1.1.7 and P.1\n\nP.1 detected in Manaus on Jan 12, 2021\n\nP.1 lineage, accrued ten unique spike protein mutations,\n\nIncluding E484K \n\nP.2 lineage also detected Manaus\n\nP.2 independently accrued the spike E484K mutation\n\nIn-vitro evidence that E484K mutation reduces neutralisation by polyclonal antibodies in convalescent sera\n\nAntigenic escape\n\nFourth factor, increased transmissibility\n\nSARS-CoV-2 lineages circulating in the second wave might have higher inherent transmissibility\n\nEg. Relative prevalence of P.1 lineage, up to 42% by  December, 2020\n\nP.1 lineage\n\nShares several independently acquired mutations\n\nB.1.1.7 (N501)\n\nB.1.325 (K417N/T, E484K, N501Y)\n\nConclusions\n\nVariants need to be quickly investigated\n\nGenetic, immunological, clinical, and epidemiological characteristics\n\nSerological and genomic surveillance in Manaus is a priority\n\nDetermining vaccine is also crucial\nRapid sharing of lineage-specific frequencies underlying reinfection", "link": "https://www.youtube.com/watch?v=SnnLZAMH_ho", "date_published": "2021-02-09 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "US possible resurgence, SA possible mistake", "description": "Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States\n\nCalifornia, 7 February \n\nhttps://www.medrxiv.org/content/10.1101/2021.02.06.21251159v1\n\nB.1.1.7 variant of SARS-CoV-2, has gained a strong foothold across the world\n\nDetection of the variant increased at a logistic rate similar to those observed elsewhere\n\nDoubling rate of a little over a week\n\nIncreased transmission rate of 35-45%\n\nSeveral independent introductions\n\nFrom late November 2020\n\nOnward community transmission, 40 states\n\nU.S. is on a similar trajectory as other countries where B.1.1.7 rapidly became the dominant SARS-CoV-2 variant\n\nRequiring immediate and decisive action to minimize COVID-19 morbidity and mortality\n\nFlorida\n\nhttps://twitter.com/DrEricDing?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1358645754248761346%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fnews.sky.com%2Fstory%2Fuk-covid-news-latest-updates-on-coronavirus-lockdown-and-vaccine-12212131\nSuper Bowl parties in Tampa (Dr Eric Feigl-Ding)\n\nHundreds of people, tightly packed, not wearing masks\n\nB117 is becoming dominant in Florida\n\nQuarantine for 14 days\n\n\nSouth Africa suspends Oxford AZ vaccine\n\nhttps://www.washingtonpost.com/world/europe/astrazeneca-oxford-vaccine-south-african-variant/2021/02/07/e82127f8-6948-11eb-a66e-e27046e9e898_story.html\n\nhttps://www.news24.com/health24/medical/infectious-diseases/coronavirus/results-from-novavax-vaccine-trials-in-the-uk-and-south-africa-differ-why-and-does-it-matter-20210202\n\nhttps://www.wits.ac.za/covid19/covid19-news/latest/oxford-covid-19-vaccine-trial-results.html\n\nOne million doses arrived\n\nMinimal protection against SA variant\n\nHealth Minister Zweli Mkhize, rollout paused\n\nVariant became dominant in November\n\nNo significant protection against illness, but all the cases of disease were mild or moderate\n\nVaccinated people will probably still allow ongoing transmission\n\nAs has been recently reported in those with prior infection\n\nThe study\n\nWitwatersrand and Oxford\n\nN = 2,000\n\nExamined adults between 18 and 64\n\nSeven sites in South Africa\n\nLast summer and fall\n\nB.1.351 (92% of all current cases in SA)\n\nEeek mutation, E484K\n\nE = Glutamate\n\nK = Lysine\n\nN501Y as well\n\nThree US states, Virginia\n\nSA variant in the UK\n\nhttps://news.sky.com/story/uk-covid-news-latest-updates-on-coronavirus-lockdown-and-vaccine-12212131\n\nCases, 147\n\n\nVaccine group\n\n19 cases of covid-19 caused by the variant\n\nMild disease was defined as at least one symptom of COVID-19\n\n\nPlacebo group\n\n20 cases\n\nSuggests 10% effective\n\nOr 22%\n\nParticipants in the trial were young and healthy\n\nMedian age 31\n\nTherefore, severe disease protection unknown\n\nNovavax and Johnson & Johnson, 50 to 60%\n\nJanssen, (J and J) protected against moderate to severe disease\n\nMight need to move from hoped for herd immunity to individual severe disease protection\n\nVaccine after effects\n\nFebruary 4, 2021\n\nhttps://covid.joinzoe.com/post/vaccine-after-effects-more-common-in-those-who-already-had-covid\n\nhttps://covid.joinzoe.com/post/covid-vaccine-pfizer-effects\n\n\nLikelihood of experience one or more mild systemic after effects\n\nN = 280,000\n\nFrom a Pfizer/BioNTech vaccine dose\n\nData comes from a sub-sample, n = 40,000\n\nLargest study group outside of trials\n\nUp to 4th January, many HCWs\n\nNot previously infected, 19%\n\nPreviously infected, 33%\n\nSystemic after effects, Pfizer/BioNTech\n\nFatigue 9%\n\nHeadache 8%\n\nChills or shivers 4%\n\nMost mild systemic after effects appeared in the first two days\n\nOnly 3% of people have any after effects beyond three days\n\nLocal effects, pain or swelling\n\nAfter the first dose, 37%\n\nAfter the second dose, 45%\n\nAt least one systemic effect (within 7 days)\n\nAfter the first dose, 14%\n\nAfter the second dose, 22%\n\nMen, 13%\n\nWomen, 19%\n\nUnder 55s, 21%\n\nOver 55s, 14%\n\nSame study, vaccine hesitancy\n\nOver one million app users\n\nYes, 95% \n\nUnsure or unwilling, 5%\n\nMain three reasons given by hesitant contributors\n\nLong term side effects, 50.2%\n\nLack of knowledge, 37.2%\n\nConcerns about potential adverse reactions, 30.9%", "link": "https://www.youtube.com/watch?v=dgm5n0pfQzY", "date_published": "2021-02-08 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]